{"result": {"id": "732e3d2a-a493-4635-8cc5-8e4c4361f6b8", "choices": [{"finish_reason": "stop", "index": 0, "logprobs": null, "message": {"content": "(\"entity\"<|>STATINS<|>ORGANIZATION<|>Statins are a class of lipid-lowering drugs that can cause muscle complications and require monitoring of CK levels)\n##\n(\"entity\"<|>CHOLESTEROL ABSORPTION INHIBITORS<|>ORGANIZATION<|>A class of drugs used in combination with statins to lower LDL-C levels)\n##\n(\"entity\"<|>FIBRATES<|>ORGANIZATION<|>A class of drugs including fenofibrate used to lower triglyceride levels)\n##\n(\"entity\"<|>OMEGA-3 FATTY ACIDS<|>ORGANIZATION<|>A class including IPE, EPA, and DHA used for lipid management)\n##\n(\"entity\"<|>LDL-C<|>ORGANIZATION<|>Low-density lipoprotein cholesterol, a primary target of lipid-lowering therapies)\n##\n(\"entity\"<|>TG<|>ORGANIZATION<|>Triglycerides, another lipid parameter targeted by treatments)\n##\n(\"relationship\"<|>STATINS<|>CHOLESTEROL ABSORPTION INHIBITORS<|>Often used in combination therapy for better LDL-C control<|>8)\n##\n(\"relationship\"<|>STATINS<|>PCSK9<|>PCSK9 inhibitors can be combined with statins for enhanced LDL-C reduction<|>7)\n##\n(\"relationship\"<|>STATINS<|>OMEGA-3 FATTY ACIDS<|>Sometimes combined to address both LDL-C and TG levels<|>6)\n##\n(\"relationship\"<|>FIBRATES<|>OMEGA-3 FATTY ACIDS<|>Combination used for severe hypertriglyceridemia<|>7)\n##\n(\"relationship\"<|>STATINS<|>LDL-C<|>Primary mechanism is reducing LDL-C levels<|>9)\n##\n(\"relationship\"<|>FIBRATES<|>TG<|>Primary mechanism is reducing triglyceride levels<|>9)\n##\n(\"relationship\"<|>OMEGA-3 FATTY ACIDS<|>TG<|>Effective at lowering triglyceride levels<|>8)\n<|COMPLETE|>", "refusal": null, "role": "assistant", "annotations": null, "audio": null, "function_call": null, "tool_calls": null}}], "created": 1752165881, "model": "deepseek-chat", "object": "chat.completion", "service_tier": null, "system_fingerprint": "fp_8802369eaa_prod0623_fp8_kvcache", "usage": {"completion_tokens": 489, "prompt_tokens": 2858, "total_tokens": 3347, "completion_tokens_details": null, "prompt_tokens_details": {"audio_tokens": null, "cached_tokens": 2816}, "prompt_cache_hit_tokens": 2816, "prompt_cache_miss_tokens": 42}}, "input": {"messages": [{"content": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: 1~4 g/d\t　胃肠道反应，大剂量 可能增加轻微出血、 新发心房颤动风险\n　烟酸及 其同类 物\t烟酸缓释片\t0.375~1.000 g，\n1 次 /d\t颜面潮红、皮肤瘙痒、 皮疹、肝脏损害、高尿\n\t阿昔莫司\t0.25~0.50 g，\n2 次 /d\t　酸血症、高血糖、棘皮 症和消化道不适等\n　　注：IPE= 二十碳五烯酸乙酯，EPA= 二十碳五烯酸，DHA= 二十二 碳六烯酸。\n4.3    降脂药物的联合应用\n　　降脂药物联合应用是当前血脂异常干预策略的趋 势，主要目的是提高血脂达标率，进一步降低 ASCVD 风险，减少药物不良反应。目前可选择的降脂药物主要 联合应用方案见表 5。也可使用他汀类药物或 / 和胆固\n\n\n他汀类药物不良反应\n　　　　　　　　　　　　　　　　　　　　　　\n\n肌肉并发症\n\n\n无症状            有症状\n立即停用他汀类药物；检测 CK、尿肌红蛋白、肾功能\n\n立即转诊\n　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　　\n\n　症状消失且  CK 恢复正常\n\n换用另一种代谢途 径的他汀类药物\n注：ALT= 丙氨酸氨基转移酶，AST= 天冬氨酸氨基转移酶，ULN= 参考值上限。\n图 4    他汀类药物不良反应处理原则\nFigure 4     Management of adverse reactions to statins\n\n\n\n·2434 · https://www.chinagp.net    E-mail: zgqkyx@chinagp.net.cn\n\n\n\tJuly 2024，Vol.27 No.20     Chinese General Practice \n\n\n表 5    降脂药物的联合应用策略\nTable 5    Combination of lipid-lowering drugs\n联合应用策略 a\t适用情况\t安全性关注点\n他汀类药物 + 胆固醇吸收抑制剂\t单药治疗后 LDL-C 不达标\t常规监测\n他汀类药物 +PCSK9 抑制剂\t单药治疗后 LDL-C 不达标\t常规监测\n他汀类药物 + 胆固醇吸收抑制剂 +PCSK9 抑制剂\t双联用药后 LDL-C 不达标\t常规监测\n他汀类药物 +ω-3 脂肪酸（IPE、EPA+DHA）或非诺贝特\tLDL-C 达标、TG 2.3~5.7 mmol/L\t心房颤动、出血、肾功能\n贝特类药物 +ω-3 脂肪酸（IPE、EPA+DHA）\t单药治疗后 TG ≥ 5.7 mmol/L\t常规监测\n注：PCSK9= 前蛋白转化酶枯草溶菌素 9；a 联合应用策略中的他汀类药物均指中等强度他汀类药物（具体药物和剂量见表 3）。\n\n\n醇吸收抑制剂固定复方制剂进一步提高依从性。\n5    特定人群的血脂管理\n5.1    高血压患者\n　　高血压患者能从强化降脂中明显获益。应根据  ASCVD 危险分层确定高血压患者相应的 LDL-C 目标值。 对于高血压合并危\n######################\nOutput:", "role": "user"}, {"role": "assistant", "content": "(\"entity\"<|>IPE<|>ORGANIZATION<|>IPE is a type of ethyl eicosapentaenoic acid used in lipid-lowering treatments)\n##\n(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA is eicosapentaenoic acid, a component used in lipid-lowering treatments)\n##\n(\"entity\"<|>DHA<|>ORGANIZATION<|>DHA is docosahexaenoic acid, a component used in lipid-lowering treatments)\n##\n(\"entity\"<|>PCSK9<|>ORGANIZATION<|>PCSK9 is a protein targeted by inhibitors used in lipid-lowering treatments)\n##\n(\"entity\"<|>ASCVD<|>EVENT<|>ASCVD is a cardiovascular disease condition targeted by lipid-lowering treatments)\n##\n(\"relationship\"<|>IPE<|>EPA<|>IPE and EPA are both components used in lipid-lowering treatments<|>5)\n##\n(\"relationship\"<|>EPA<|>DHA<|>EPA and DHA are both omega-3 fatty acids used in lipid-lowering treatments<|>5)\n##\n(\"relationship\"<|>IPE<|>DHA<|>IPE and DHA are both components used in lipid-lowering treatments<|>5)\n##\n(\"relationship\"<|>PCSK9<|>ASCVD<|>PCSK9 inhibitors are used to manage ASCVD risk<|>7)\n<|COMPLETE|>"}, {"content": "MANY entities and relationships were missed in the last extraction. Remember to ONLY emit entities that match any of the previously extracted types. Add them below using the same format:\n", "role": "user"}], "parameters": {"model": "deepseek-chat", "frequency_penalty": 0.0, "max_tokens": null, "n": 1, "presence_penalty": 0.0, "temperature": 0.0, "top_p": 1.0}}, "key": "chat_extract-continuation-0_5bd5c023ac1d610e08258c2296c0b504edeedec44445c7b131c20dd2b4c576e6_v2"}